Categories
Cannabis

US labor market sizzles with blowout job growth, solid wage gains

By Lucia Mutikani

WASHINGTON (Reuters) – U.S. job growth accelerated in January and wages increased by the most in nearly two years, signs of persistent strength in the labor market that could make it difficult for the Federal Reserve to start cutting interest rates in May as currently envisaged by financial markets.

The closely watched employment report from the Labor Department on Friday also showed the unemployment rate at 3.7% last month, remaining below 4% for two consecutive years, the longest such stretch in more than 50 years. More jobs were created in 2023 than previously estimated. January’s blowout job count and large wage gains dashed prospects of a rate cut next month. Financial markets lowered the odds of a May cut.

Resilient demand and strong worker productivity are likely encouraging businesses to hire and retain more employees, a trend that could shield the economy from a recession this year.

“Given the Fed now wants strong job growth, as (Fed Chair) Jerome Powell told us just two days ago, this report should not discourage the Fed from cutting rates,” said Chris Low, chief economist at FHN Financial in New York. “By the same token, however, it is not going to encourage them to rush into rate cutting.”

Nonfarm payrolls increased by 353,000 jobs last month, the largest gain in a year, the Labor Department’s Bureau of Labor Statistics said. The economy added 126,000 more jobs in November and December than previously reported. Payrolls shrugged off the drag from winter storms, which reduced the average workweek.

Though annual “benchmark” revisions showed 266,000 fewer jobs were created in the 12 months through March 2023 than previously reported, employment gains last year totaled 3.1 million. Before the revisions, the job count for 2023 had been estimated at 2.7 million.

Economists polled by Reuters had forecast payrolls increasing 180,000 last month. Estimates ranged from 120,000 to 290,000. Job growth in January was above the monthly average of 255,000 in 2023. Roughly 100,000 jobs per month are needed to keep up with growth in the working age population.

The report suggested that economic growth momentum from the fourth quarter spilled over into the new year. It also challenged the notion that the economy was heading for a “soft-landing.” President Joe Biden welcomed the report saying “America’s economy is the strongest in the world.”

Average hourly earnings increased 0.6% last month, the biggest gain since March 2022, after rising 0.4% in December. In the 12 months through January, wages increased 4.5% after advancing 4.3% in December.

Wage growth is running ahead of the 3.0% to 3.5% range that most policymakers view as consistent with the U.S. central bank’s 2% inflation target, supporting views that the Fed will not move quickly to lower borrowing costs.

Financial markets now see a less than 60% chance of the Fed cutting rates at its April 30 and May 1 meeting. The Fed left interest rates unchanged on Wednesday, but Chair Jerome Powell told reporters that rates had peaked. Since March 2022, the central bank has raised its policy rate by 525 basis points to the current 5.25% to 5.50% range.

Stocks on Wall Street were trading higher. The dollar rose against a basket of currencies. U.S. Treasury prices fell.

BROAD GAINS

Most economists were dismissive of recent high-profile layoffs, including 12,000 job cuts announced by United Parcel Service this week, arguing that the focus should be on worker productivity, which has exceeded a 3% annualized growth pace for three straight quarters, and cooling labor costs.

Employers are generally wary of sending workers home following difficulties finding labor during and after the COVID-19 pandemic. But some companies, which enjoyed a boom in business during the pandemic, are laying off workers as conditions return to normal.

“We know that most layoffs in recent years were from cost cutting and not from weaker demand,” said Jeffrey Roach, chief economist at LPL Financial in Charlotte, North Carolina. “This means businesses are in a good position despite the macro headwinds and uncertainty about growth expectations.”

Employment gains last month were across the board, with nearly two-thirds of industries adding jobs, the most in a year. Professional and business services added 74,000 jobs. Temporary help services employment, a harbinger for future hiring rebounded by 3,900, ending 21 straight months of declines.

Healthcare payrolls rose by 70,000 jobs, spread across ambulatory, hospitals as well as nursing and residential care facilities. Retail trade employment increased by 45,000 jobs, while manufacturing hired 23,000 more workers. Government payrolls increased by 36,000, driven by federal government hiring as well as local government, excluding education.

There were also job gains in construction, transportation and warehousing, utilities, leisure and hospitality sectors. But the mining and logging industry shed 6,000 jobs.

The average workweek declined by 0.2 hour to 34.1 hours. Outside the pandemic recession, that was the shortest since June 2010. Some economists viewed this as a sign that layoffs were imminent, but others blamed the winter storms. About 553,000 people did not report for work in mid-January because of bad weather, the largest for any January since 2011.

The unemployment rate was at 3.7% in January. New population estimates were incorporated into the household survey, from which the unemployment rate is derived, creating a break in the series. The population controls had no impact on the jobless rate, which was at 3.7% in December.

There was also no impact on the labor force participation rate, or the proportion of working-age Americans who have a job or are looking for one, which held at 62.5%. But the size of the civilian labor force was reduced by 299,000. There was an uptick in the number of people working part-time for economic reasons and those experiencing longer spells of unemployment.

“The overall picture looks to be one of a still quite strong labor market, and an economy starting 2024 with plenty of forward momentum,” said Michael Feroli, chief U.S. economist at JPMorgan in New York.

(Reporting by Lucia Mutikani; Editing by Chizu Nomiyama and Andrea Ricci)

tagreuters.com2024binary_LYNXMPEK1103Q-VIEWIMAGE

Categories
Cannabis

Mexico’s Weed ‘Nuns’ Want to Take the Plant Back From the Narcos

By Sarah Kinosian

(Reuters) – Beneath each full moon on the outskirts of a village in central Mexico, a group of women in nun habits circle around a roaring fire, cleanse themselves with burned sage, and give thanks for the moon, animals, and plants.

Then they inhale deeply from a joint and blow clouds of marijuana into the flames.

Despite their clothing, the women are not Catholic or any other religion. They are part of an international group founded in 2014 called Sisters of the Valley, which has pledged to spread the gospel of the healing powers of cannabis.

In the United States, where around two dozen states have legalized recreational marijuana, the group has also launched a successful small business, selling CBD tinctures, oils and salves online, and raking in over $500,000 last year.

But in Mexico, where a drug war has ravaged the country and Christianity is embedded in society, the image of a marijuana-smoking nun is more an act of rebellion, the women say.

The sisters frequently post on social media, primarily Instagram, where they can be seen caring for cannabis crops, giving workshops, and attending cannabis-related events.

Their product sales are a fraction of that of their U.S. sisters – around $10,000 annually.

While prominent online, the women – five in total – are cautious about giving away too much about the location of their operations. They conduct business out of a two-story concrete false storefront with one finished room.

Because cannabis sits in a legal gray area in Mexico and much of its production is still tied to criminal organizations, they worry police or local gangsters could arrive to threaten or extort them.

On a recent weekend when Reuters visited, the curtains remained drawn. Bundles of marijuana dried in clandestine crevices – hanging from a tucked-away laundry line, or hidden in the stove.

“The Sisterhood is in a totally different context here in Mexico – because of how religious the country is and because of the plant’s ties to cartels,” said one of the nuns, who uses the moniker “Sister Bernardet” online and asked not to give her name for fear of reprisal. In her main job as a homeopathic practitioner, she prescribes marijuana to her patients with cancer, joint pain and insomnia.

“We want to take the plant back from the narcos,” she said.

The Sisters fashion themselves after a lay religious movement, the Beguines, that dates back to the Middle Ages. The group, made up of single women, devoted itself to spirituality, scholarship and charity, but took no formal vows.

The Sisters globally say they wear habits to project uniformity and respect for the plant, but they also know it catches media attention.

Under the guidance of Alehli Paz, a chemist and marijuana researcher working with the group, the Sisters in Mexico grow a modest crop.

They pot plants in old paint buckets and place them in rows between four unfinished concrete walls on a rooftop.

Once grown, the Sisters move the plants to walled-off private gardens they identified with help from supportive older women in the community.

Their participation is limited to weekends they can steal away from their lives. Powered by a seemingly never-ending stream of joints and packed pipe bowls, the women spend time at the farm pruning plants, producing cannabinoid salves or weighing and storing different strains, labeled and dated, in old glass coffee jars.

They also visit others in Mexico City pushing for full legalization in the growing cannabis community, or give workshops that touch on everything from how to make weed infusions to the chemistry behind the plant. 

Business potential aside, they argue that the fight against drugs in Latin America has been a failure, leading to widespread violence and mass incarceration.

But in a roughly 75% Catholic majority, conservative country locked in a drug war with criminal groups for nearly 20 years, joining the Sisters has created tension in nearly all of the women’s families.

Its founder in Mexico, who calls herself “Sister Camilla” online and declined to give her name, grew up in an evangelical household and left home at 16 due, in part, to her mother’s strict religious code, she said. When she started Sisters of the Valley Mexico, the relationship became even more strained. 

“It was hard for her to accept,” she said. “She had certain ideas, heavily shaped by religion.” 

But today, after lengthy discussions about the plant and the legalization movement, her mother is pivotal to the group’s operations, helping to maintain the farm and offering other logistical support, she said.

For another nun who works as a church secretary, uses the moniker “Sister Kika” and asked her name not be used, the mission is clear. “It’s time to put an end to this stupidity,” she said.

(Photography by Raquel Cunha; Reporting and writing by Sarah Kinosian; Additional reporting by Andrea Rodriguez; Editing by Rosalba O’Brien)

tagreuters.com2023binary_LYNXMPEJBQ07D-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07I-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07J-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07K-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07L-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07P-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07Q-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07R-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07T-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07U-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07V-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ081-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ080-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07Y-VIEWIMAGE
tagreuters.com2023binary_LYNXMPEJBQ07X-VIEWIMAGE
Categories
Cannabis

Canopy Growth posts smaller Q1 core loss, reiterates going concern doubts

By Sourasis Bose

(Reuters) -Canopy Growth again raised doubts about its ability to stay afloat as the Canadian pot producer’s loss-making streak continued in the first quarter.

Despite a strong start following the legalization of pot in Canada in 2018, the country’s cannabis industry has faced intense competition from cheaper marijuana that is sourced illegally.

Canopy had first raised the going concern doubts in June.

The company has taken several initiatives to turn profitable, including job cuts, exits from some international markets, store closures and divestiture of its retail business across Canada.

The Smiths Fall, Ontario-based company had C$533.3 million in cash and cash equivalents as of June 30, compared with C$677 million at the end of March.

Its total debt was C$1.05 billion at the end of the reported quarter.

The cannabis firm’s quarterly net revenue grew 3% to C$108.7 million, aided by expansion in its BioSteel segment, which makes sports nutrition products.

But its second-quarter sales are expected to be lower sequentially due to seasonality, Chief Financial Officer Judy Hong said in a post-earnings conference call.

The company is also facing an investigation from the U.S. Securities and Exchange Commission over the reporting of revenue from BioSteel.

Canopy had launched an internal review in June for BioSteel and let go of several members of the segment’s leadership team following completion of the assessment.

The company’s adjusted core loss narrowed to C$57.8 million for the three months ended June 30, compared with a loss of C$79 million a year earlier, aided by cost reduction.

The company lowered costs by C$47 million during the quarter, though it saw higher warehousing and production expenses associated with the BioSteel manufacturing facility located in Verona, Virginia.

(Reporting by Sourasis Bose in Bengaluru; Editing by Shinjini Ganguli and Shilpi Majumdar)

Categories
Cannabis

Altria-backed cannabis producer Cronos explores sale

By Anirban Sen

NEW YORK (Reuters) -Cronos Group Inc, the Canadian cannabis producer backed by cigarette maker Altria Group Inc, confirmed on Thursday it is in talks with potential buyers to explore a sale of the company, after Reuters reported on the talks.

Cronos is working with a financial adviser to handle expressions of interest in a deal from other companies, including U.S.-based peer Curaleaf Holdings Inc, according to people familiar with the matter.

The sources requested anonymity because the discussions are confidential, and they cautioned that no transaction is certain.

In a statement, Cronos said it “is in the initial stages of reviewing these indications of interest.”

Curaleaf declined to comment. Spokespeople for Altria did not immediately respond to a request for comment.

Shares of Cronos jumped as much as 25% in Toronto on the news, before giving back all gains and closing lower at $1.88, giving it a market value of C$954.62 million ($714.38 million). So far this year, the shares have lost a quarter of their value.

The future of the cannabis industry is uncertain as more favorable regulatory regimes in North America have fueled fierce competition among more companies.

The recreational use of cannabis is now legal in 23 U.S. states. Growing and selling marijuana remains illegal under U.S. federal law, although President Joe Biden’s administration has signaled it is seeking a review on how the drug is classified.

U.S. lawmakers have also been considering making it easier for the industry to access banking services.

For the first quarter, Cronos posted a net loss of $19.3 million, compared with a loss of $32.7 million a year ago. Net revenue declined 20% to $20.1 million. Cronos has total cash, including short-term investments, of about $836.43 million, according to its first-quarter report.

Altria, which holds a 41% stake in Cronos, invested $1.8 billion in the company in 2019.

($1 = 1.3363 Canadian dollars)

(Reporting by Anirban Sen in New York; Additional reporting by Abigail Summerville in New York; Editing by Leslie Adler, Richard Chang and David Gregorio)

Categories
Cannabis

Canopy Growth sells California facility amid liquidity worries

(Reuters) – Pot producer Canopy Growth said on Thursday it has completed the sale of its facility in Modesto, California as a part of its divestitures to raise funding amid liquidity concerns.

The sale of the facility was the fifth such deal since April 1 and has generated C$81 million ($61.10 million), the company said.

“The proceeds from this transaction further the achievement of our target of C$150 million in total proceeds from facility divestitures by the end of September 2023,” said CEO David Klein in a statement.

Canopy Growth’s shares, which have slumped more than 80% this year, have been under added pressure since last week after the company raised ‘going concern’ doubts citing systemic regulatory issues, continued battle with the illicit marijuana market and delays in government action.

Analysts have questioned the cannabis producer’s ability to reduce cash-burn and turnaround operations. Brokerage Benchmark slashed its price target on Canopy to zero earlier this week.

($1 = 1.3258 Canadian dollars)

(Reporting by Sourasis Bose in Bengaluru; Editing by Krishna Chandra Eluri)

Categories
Cannabis

Trulieve Cannabis Misses Revenue Estimates on Weak Demand

(Reuters) -Trulieve Cannabis Corp posted a bigger-than-expected fall in first-quarter revenue on Wednesday, as demand for pot and related products weakened amid rising recession fears.

Recent banking failures and interest rate hikes have raised fears of the U.S. economy tipping into recession, prompting many customers to cut back on spending, especially on recreational products including cannabis.

Pot producers are also struggling with lower pricing, increased competition and higher input costs, amid a lack of access to capital and the banking system.

“The company experienced increased competition and promotional activity in certain markets, including Florida, Pennsylvania and Massachusetts,” Trulieve Cannabis said in a filing.

The Florida-based company said its net loss doubled from a year earlier to $64 million in the March quarter, with operating expenses up 8% at $163 million.

Revenue fell 9% to $289 million, missing analysts’ average expectations of $293 million, according to Refinitiv data. The company said the fall was due to a decline in both retail and wholesale revenues.

Shares of Trulieve are down 30.1% year-to-date.

(Reporting by Ankit Kumar; Editing by Subhranshu Sahu)

Categories
Business Canada Cannabis

Canopy Growth sheds 35% of Work Force in Canada

By Ankit Kumar

(Reuters) -Canopy Growth Corp said on Thursday it would shed assets in Canada and cut 800 job positions as part of the pot producer’s efforts to reduce costs and turn profitable.

Shares of the company, which reported a bigger quarterly loss, plunged 16.6% to C$3.06 at the closing of trade.

The company has been cutting costs through layoffs, exit from some international markets, store closures and divestiture of its retail business across Canada.

The company expects to save C$140 million ($104.10 million)to C$160 million over the next 12 months.

Its streamlining efforts in Canada include exiting cannabis flower cultivation in its Smiths Falls, Ontario facility, ceasing the sourcing of cannabis flower from the Quebec facility, and moving to a third-party sourcing model for cannabis beverages, edibles, vapes and extracts.

The company expects to complete the operational changes in the second quarter of fiscal 2024 and record restructuring-related pretax charges of C$425 million to C$525 million in the current quarter and the first half of fiscal 2024.

Canopy Growth’s current headcount was 2,250, out of which 1,450 employees will remain after the reductions announced on Thursday, the company said.

“Canopy is now in a position where its success will largely depend on investor enthusiasm amid an environment where cannabis sentiment is at best apathetic,” Stifel analyst Andrew Carter said in a note.

The company’s adjusted core loss widened to C$87.5 million in the quarter ended Dec. 31, from C$67.4 million a year earlier.

Smaller rival Aurora Cannabis Inc, however, reported an adjusted core profit of C$1.4 million, compared to a loss of C$7.1 million in the year-ago quarter, helped by higher revenue and reduction in expenses.

($1 = 1.3449 Canadian dollars)

(Reporting by Ankit Kumar, additional reporting by Sourasis Bose; Editing by Maju Samuel and Shailesh Kuber)

tagreuters.com2023binary_LYNXMPEJ180KT-VIEWIMAGE

Categories
Cannabis

MediPharm Labs Receives Australian Licence to Import Drugs

Photo by Catarina Sousa on Pexels.com

BARRIE, Ontario, Jan. 31, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce the receipt of a key importation licence for its Australian business. This licence is a critical step to building the Company’s international supply chain that will be used to create additional synergies between MediPharm Labs’ Canadian and Australian operations.

The Australian Department of Health, Drug Control Section has issued an import licence to MediPharm Labs Australia Pty. Ltd. (“MediPharm Labs Australia”), a subsidiary of MediPharm Labs, for the importation of drugs listed in Schedule 4 of the Customs (Prohibited Imports) Regulations 1956, which includes cannabis, cannabinoids and cannabis resin. Upon the receipt of the applicable import permits, this licence will allow for the importation of cannabis, cannabinoids and cannabis resin from MediPharm Labs in Canada, and other global authorized exporters, for finalization into tinctures and other product forms in Australia.

“Receiving this licence is an important milestone as we continue to build a multi-jurisdictional GMP-certified pharmaceutical-quality platform to serve the world’s most attractive medical cannabis markets”, said Pat McCutcheon, Chief Executive Officer of MediPharm Labs. “With the initial phases of our Australian facility built-out, we are on track to establishing a global cannabis supply chain leveraging our GMP-certified Canadian facility, technology and access to high quality, fully traceable, cannabis biomass converted to pharma quality concentrates in Canada, to supply MediPharm Labs Australia, its local market, and other permissible global jurisdictions.”

Upon MediPharm Labs Australia receiving its GMP certificate from the Therapeutic Goods Association (“TGA”), the Company will be positioned to leverage a global supply chain to sell cannabis APIs and finished products to countries across the EU, including Germany, due to a Mutual Recognition Agreement between Australia and the EU.

Australia is one of the 49 member countries of Pharmaceutical Inspection Co-operation Scheme (PIC/S), TGA GMP certification could also allow for the easier movement of global product. For example, in Brazil, where new cannabis regulations will be effective April 2020, the Agência Nacional de Vigilância Sanitária (ANVISA) has stated that PIC/s approved cannabis facilities will be permitted to import medical cannabis into the Brazilian market. This recognition will be in effect until 2022 at which time ANVISA will develop their own GMP certification program for international cannabis imports.

Progress in Australia

Australian Facility GMP and Commercialization – Since receiving its State Licences for cannabis substances from the Victorian Department of Health and Human Services, and finishing the initial phases of construction of its 10,000 sq. ft. specialized extraction facility in Wonthaggi in December 2019, MediPharm Labs Australia has completed the first of two stages of a TGA Audit (related to its storage facilities and release for supply) and submitted an evidence package in January 2020. The next TGA Audits of its full production capabilities (including laboratory) are expected in the first half of 2020. This positions the facility to receive Australian GMP certification and full production by H2 2020.

As part of the stepwise build out of its facility, MediPharm Labs Australia recently operationalized its multi-phase supercritical COextraction equipment, installed and started Installation Qualification and Operational Qualification of its vacuum ovens and milling machines, and is in the process of qualifying its softgel capsule filling equipment.

Canadian Facility GMP and Export Readiness – On December 13, 2019, the Company received notification from the Australian TGA that its Canadian manufacturing facility met the requirements for GMP as a Medicines Manufacturer of both Cannabis as a Medicine (oral liquids) and Cannabis as an Active Pharmaceutical Ingredient (“API”). Although this certification specifically applies to the Australian market, it adds to a body of evidence that will assist MediPharm Labs qualifying to supply other medical cannabis markets globally.

About MediPharm Labs

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian extraction facility. MediPharm Labs Australia was established in 2017.

For further information, please contact:
Laura Lepore, VP, Investor Relations and Communications
Telephone: 416-913-7425 ext. 1525
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, importation of drugs (including various forms of cannabis) by MediPharm Labs Australia, receipt of importation permits by MediPharm Labs Australia, realization of synergies between MediPharm Labs and MediPharm Labs Australia, finalization of cannabis products within Australia, serving the global medical cannabis markets, establishment of a global supply chain, receipt of TGA GMP and full production authorization by H2 2020 by MediPharm Labs Australia, regulatory developments in Brazil, utilization of the PIC/S network and/or mutual recognition agreements to allow global product flow, IQ/OQ and qualification of equipment. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at http://www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

Categories
Cannabis

MinnMed Launches Flavored Oral Spray Cannabis Products

New product line includes five oral spray options to best fit the needs of every patient

MINNEAPOLIS, Jan. 30, 2020 /PRNewswire/ — Minnesota Medical Solutions (“MinnMed” or “the Company”) today announced that the Company has introduced a new product line of flavored oral sprays. MinnMed Oral Sprays will be offered in the most diverse range currently available in Minnesota.

MinnMed’s new oral sprays are a direct result of patients calling for a variety of medical cannabis products that are convenient and simple to use. Many medical cannabis patients require a fast and leveled onset of relief that pure cannabis oils can provide. At MinnMed, we pride ourselves in providing our patients with a diverse range of cannabis options to best suit their specific needs.

MinnMed Founder, Kyle Kingsley, M.D.

MinnMed is the only licensed cannabis producer in the State of Minnesota to offer patients five different flavored oral spray options. Each of the oral sprays are made with the Company’s whole plant concentrated oil, which produces highly purified cannabis oils to ensure product safety. The new product line is available in the most popular colors of the Vireo Spectrum – with ratios ranging from THC-dominant to CBD-dominant. With the help of a licensed MinnMed pharmacist, patients will determine which formulation and dosage strategy will most effectively help their qualifying medical condition.

“MinnMed is a physician-led, patient focused company that is committed to providing Minnesotans with the highest quality cannabis-based medicine through the state’s medical cannabis program,” said Gary Starr, M.D., MinnMed Deputy CEO. “In addition to the recent launch of a new line of distillate cannabis products, we are excited to offer our patients a full line of convenient oral spray products.”

The launch of oral spray cannabis products follows other recent announcements by MinnMed to make medical cannabis more accessible and affordable for Minnesotans. MinnMed recently announced substantial price cuts on many medical cannabis products, including a new line of distillate cannabis products, by as much as 30% for all patients. In addition, MinnMed is focused on attracting new patients to the medical cannabis program by providing a 50% discount for all first-time patients on purchases up to $200. For more information, please visit www.minnmed.com.

About Minnesota Medical Solutions

Minnesota Medical Solutions (“MinnMed”) is one of two licensed medical cannabis companies in Minnesota. MinnMed operates four Cannabis Patient Centers across the state and a greenhouse facility near Otsego, MN. MinnMed is a subsidiary of Vireo Health International, Inc. (“Vireo”). Vireo’s mission is to build the cannabis company of the future by bringing the best of medicine, engineering and science to the cannabis industry. Vireo’s physician-led team of more than 400 employees provides best-in-class cannabis products and customer experience. For more information about MinnMed, please visit www.minnmed.com.

Original press release

Categories
Cannabis

Leading Public Cannabis Companies Report Mixed Revenue Growth in January

Exclusive article by Alan Brochstein, CFA

The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$7.5 million per quarter (C$9.9 million). This data-driven, fact-based tracker will continually update based on new financial filings so that readers can stay up to date. Companies must file with the SEC or SEDAR to be considered for inclusion. Please note that we raised the minimum quarterly revenue in May from US$2.5 million and from US$5.0 million in October.

45 companies currently qualify for inclusion, with 29 filing in U.S dollars and 16 in the Canadian currency, which is the same as when we reported at the end of December.

In May, we began to include an additional metric, “Adjusted Operating Income”, as we detailed in our newsletter. The calculation takes the reported operating income and adjusts it for any changes in the fair value of biological assets required under IFRS accounting. We believe that this adjustment improves comparability for the companies across IFRS and GAAP accounting. We note that often operating income can include one-time items like stock compensation, inventory write-downs or public listing expenses, and we recommend that readers understand how these non-cash items can impact quarterly financials.

One trend we have observed is that many of the companies are now providing pro forma revenue as well, which is an attempt to more accurately portray the operations by taking into account the results of closed and pending acquisitions as the multi-state operator (MSO) space rapidly consolidates. Our rankings include only actual reported revenue.

For companies that report in U.S. dollars, only KushCo Holdings (OTC: KSHB) provided updated financials during January.  The company saw the vaping crisis take a toll in the near-term, as revenue dipped 26% during its fiscal Q1 ending November 30th from the prior quarter, though sales still grew 38% organically from the prior year. The company reaffirmed the guidance it had previously provided in early November for FY20 revenue to be in the range of $230-250 million.

American Dollar Reporting – Public Cannabis Company Revenue Tracker

During February, we expect reports from Acreage Holdings (CSE: ACRG) (OTC: ACRGF), AYR Strategies (CSE: AYR) (OTC: AYRSF), GW Pharma (NASDAQ: GWPH) and MedMen Enterprises (CSE: MMEN) (OTC: MMNFF). Acreage has scheduled a call for its Q4 financials on February 26th, while AYR Strategies will discuss its Q4 financials the following day. GW Pharma pre-announced its Q4 revenue earlier this month, with its preliminary estimate that it will be  $108 million, which would represent growth of 19% sequentially. A year ago, during a quarter that marked the launch of Epidiolex late in the quarter, the company generated revenue of $6.65 million.The company will host a call, as yet unscheduled, on February 25th.  MedMen will report its fiscal 2020 Q2 after the close on February 26th.

Of the companies that report in Canadian dollars, LPs Aphria (TSX: APHA) (NYSE: APHA) and Organigram (TSX: OGI) (NASDAQ: OGI), Florida operator Liberty Health Sciences (CSE: LHS) (OTC: LHSIF) and National Access Cannabis (TSXV: META) (OTC: NACNF) provided financial updates during January. Aphria fell short of expectations for revenue of C$130 million in its fiscal Q2, with the total of C$120.6  million including C$33.7 million of cannabis revenue and pharmaceutical distribution representing the balance at C$86.4 million. The company grew cannabis revenue sequentially by 9%. For the fiscal year ending in May, Aphria reduced revenue and EBITDA guidance to C$575-625 million and C$35-42 million, respectively. Previiously, the company had forecast revenue to be C$650-700 million, with EBITDA at C$88-95 million. Organigram’s Q1 revenue sharply exceeded expectations of C$21.3 million as the company resumed growth after a weak Q4. Wholesale revenue accounted for about 36% of its overall revenue. Liberty Health continued its strong growth, which was driven by an increase in the number of dispensaries. The company accelerated its profitability from the prior quarter, with adjusted operating earnings equaling about 15% of sales. National Access (dba Meta Growth) had experienced flat sequential revenue growth in its fiscal Q4 ending August 31st, and, despite having more stores open during its fiscal Q1 ending November 30th, the company saw revenue decline by 7% as its operating loss expanded.

Canadian Dollar Reporting – Public Cannabis Company Revenue Tracker

During February, we expect financial updates from LPs Aurora Cannabis (TSX: ACB) (NYSE: ACB), Canopy Growth (TSX: WEED) (NYSE: CGC), Cronos Group (TSX: CRON) (NASDAQ: CRON) and Supreme Cannabis (TSX: FIRE) (OTC: SPRWF). Aurora Cannabis, according to Sentieo, is expected to see revenue expand to C$81 million in its fiscal Q2 from the prior quarter, while Canopy Growth is expected to maintain the leadership among LPs with fiscal Q3 revenue reaching a record C$104 million. Neither company has scheduled their conference calls yet. Analysts project Q4 revenue for Cronos Group to have been $17.4 million, which would represent growth of 37% from the prior quarter. The company has scheduled a call for February 27th. Supreme Cannabis is expected to have generated revenue of $11 million in its fiscal Q2, similar to the results from its first quarter. The company will report on February 13th.